Aktuelles zur Therapieumstellung bei Multipler Sklerose

Abstract

In recent years the approval of new substances has led to a substantial increase in the number of course-modifying immunotherapies available for multiple sclerosis. Therapy conversion therefore represents an increasing challenge. The treatment options sometimes show complex adverse effect profiles and necessitate a long-term and comprehensive monitoring. This article presents an overview of therapy conversion of immunotherapies for multiple sclerosis in accordance with the recommendations of the Disease-Related Competence Network for Multiple Sclerosis and the German Multiple Sclerosis Society as well as the guidelines on diagnostics and therapy for multiple sclerosis of the German Society of Neurology and the latest research results. At the present point in time it should be noted that no studies have been carried out for most of the approaches for therapy conversion given here; however, the recommendations are based on theoretical considerations and therefore correspond to recommendations at the level of expert consensus, which is currently essential for the clinical daily routine.

Neuroimmunological Registries in Germany

“…In addition to scientific investigations, the collaboration within the KKNMS has led to consented recommendations addressing therapy monitoring for immunotherapies as well as the issue of the change of therapy [34,35]. This contributes to improvement of patient safety and possibly therapy optimization.…”

Neuroimmunologische Register in Deutschland

“…Neben den wissenschaftlichen Untersuchungen hat die Zusammenarbeit innerhalb des KKNMS auch zu konsentierten alltagsrelevanten Empfehlungen geführt, die vor allem das Therapiemonitoring für Immuntherapien sowie die Frage der Therapieumstellung bearbeiten und somit einen Beitrag zur Verbesserung der Therapiesicherheit für die Patienten leisten [34,35]. Das Register nutzt den in ▶ Abb.…”